Cavorsi Robert 4

What Happened Robert Cavorsi, Vice President, Strategy at Organogenesis (ORGO), received equity awards on Feb 18, 2026: 93,750 RSUs, 16,290 performance shares (issued on vesting), and 53,452 derivative RSU-type awards — a total of 163,492 shares acquired at $0.00. On the same date, 5,432 shares were surrendered/disposed to cover tax withholding at $3.84 per share, generating $20,859 in value for tax payment.

Key Details

• Transaction date: 2026-02-18; filing date: 2026-02-20 (filed within two days).
• Grants/acquisitions: 93,750 RSUs (A) and 53,452 derivative RSU awards (A), plus 16,290 shares from vesting/settlement of a 2025 performance award (A); all listed at $0.00 acquisition price.
• Disposal (tax withholding): 5,432 shares (F) at $3.84 = $20,859, used to satisfy tax liability.
• Total shares newly acquired (awards/settlements): 163,492.
• Shares owned after transaction: not specified in the provided filing.
• Footnotes of note:
  • F1: RSUs granted; each RSU converts to one share upon vesting; they vest in equal annual installments over four years beginning Feb 15, 2026.
  • F2: 16,290 shares issued upon vesting/settlement of a 2025 performance share award tied to performance milestones.
  • F3: (Included in filing footnotes) describes option vesting schedule (exercisable in equal annual installments over four years beginning Feb 15, 2026) — no option exercise was reported in these lines.
• Filing timeliness: appears timely (filed two days after the reported transactions).

Context The activity is primarily compensation-related (RSU and performance award grants and the settlement of a performance award). The 5,432-share disposal was a routine tax-withholding action, not an open-market sale for other purposes. For retail investors, award grants increase insider share exposure but do not necessarily signal buying intent; tax-withholdings are common and routine.